The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s oligonucleotide therapy market report forecasts the oligonucleotide therapy market size to grow to $2.1 Billion by 2027, with a CAGR (compound annual growth rate) of more than 14%.

Learn More On The Oligonucleotide Therapy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Oligonucleotide Therapy Market Size Forecast
The global oligonucleotide therapy market is expected to grow from $1.1 billion in 2022 to $1.23 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oligonucleotide therapy market is expected to grow from $2.1 billion in 2027 at a CAGR of 14.2%.

North America held the largest oligonucleotide therapy market share.

Key Oligonucleotide Therapy Market Driver ­– Rise In The Number Of Cancer Cases Globally
For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years.

Request for A Sample Of The Global Oligonucleotide Therapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

Key Oligonucleotide Therapy Market Trend – Investing In Research And Development
The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, the FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects.

Oligonucleotide Therapy Market Segment
1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes

Oligonucleotide Therapy Market Major Players and Strategie
Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holdings ASA, Sarepta Therapeutics Inc., Jazz Pharmaceuticals and Bausch & Lomb.

In August 2020, Evotec SE, a Germany based pharmaceutical drug discovery and development company, announced a strategic partnership with Secarna Pharmaceuticals GmbH & Co. KG, a Germany-based antisense oligonucleotide company specialising in addressing significant unmet medical needs in immunology and immuno-oncology. Through this partnership, the multimodality platform of Evotec is further enhanced by this strategic cooperation with Secarna. In areas with a high unmet medical need, Evotec works to identify the best possible approaches to developing disease-modifying medications, whereas Secarna is a top supplier of tested ASO technology with a special platform to enable the identification and selection of ASOs in their early stages.

The Oligonucleotide Therapy Global Market Report 2023 covers regional data on oligonucleotide therapy market size, oligonucleotide therapy market trends and drivers, opportunities, strategies, and oligonucleotide therapy market competitor analysis. The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides’ most popular application (polymerase chain reaction).

View More Reports Related To The Oligonucleotide Therapy Market –
Pain Management Devices And Therapies Global Market Report 2023
Drugs For Hormonal Replacement Therapy Drugs Global Market Report 2023
Nucleic Acid Based Gene Therapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: